Contemporary hormonal contraception and cervical cancer in women of reproductive age

Lisa Iversen1 | Shona Fielding2 | Øjvind Lidegaard3 | Philip C. Hannaford1

1Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
2Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
3Department of Gynaecology, Rigshospitalet, The Juliane Marie Centre, University of Copenhagen, Copenhagen, Denmark

Abstract
To determine cervical cancer risk associated with contemporary hormonal contraceptives, we conducted a cohort study of women aged 15 to 49 living in Denmark from 1995 to 2014, using routinely collected information about redeemed prescriptions, incident cancer and potential confounders. Poisson regression calculated adjusted cervical cancer risks among different contraceptive user groups by duration of use, time since last use, hormonal content and cancer histology. During >20 million person-years, 3643 incident cervical cancers occurred. Ever users of any hormonal contraceptives compared to never users had a relative risk (RR) of 1.19 (95% confidence interval [CI] 1.10-1.29). Increased risks were seen in current or recent users of any hormonal: RR 1.30 (95% CI 1.20-1.42) and combined: RR 1.40 (95% CI 1.28-1.53), but not progestin-only contraception: RR 0.91 (95% CI 0.78-1.07). Current or recent users of any hormonal contraception had an increased risk of both adenocarcinoma (RR 1.29, 95% CI 1.05-1.60) and squamous cancer (RR 1.31, 95% CI 1.19-1.44). The risk pattern among any hormonal and combined contraceptive users generally increased with longer duration of use and declined after stopping, possibly taking longer to disappear among prolonged users. Combined products containing different progestins had similar risks. Approximately one extra cervical cancer occurred for every 14 700 women using combined contraceptives for 1 year. Most women in our study were not vaccinated against human papillomavirus (HPV) infections. Our findings reinforce the urgent need for global interventions such as systematic screening, treatment of cervical intraepithelial neoplasia and HPV vaccination programmes to prevent cervical cancer, especially among users of combined contraceptives.

KEYWORDS
- cervical cancer
- cohort study
- combined contraceptives
- hormonal contraception
- progestin-only

INTRODUCTION

In 2018, approximately 570 000 new cases of cervical cancer (6.6% of all new female cancers), and 311 365 related deaths occurred worldwide. A necessary cause of cervical cancer is human papillomavirus...
(HPV) infection with eight types of HPV found in 91% of cases of cervical cancer worldwide. Currently available bivalent, quadrivalent and nonavalent HPV vaccines provide the opportunity to prevent a large proportion of cervical cancer cases. More than 80% of all cervical cancer cases occur in Africa, Asia, Latin America and the Caribbean. Most countries within these regions do not have an HPV immunisation programme. Vaccine shortages are ongoing and predicted to last at least until 2025 resulting in a large number of women around the world remaining at risk of HPV infection and cervical cancer.

Risk factors for cervical cancer include aspects of sexual behaviour, cigarette smoking, immunodeficiency and oral contraception. In 2019, an estimated 151 million women of reproductive age worldwide used oral contraceptives, of which roughly two-thirds lived outside Europe, North America, Australia and New Zealand. Thus, most oral contraceptive users live in countries without comprehensive HPV vaccination or cervical screening programmes. Past evidence, summarised by the International Collaboration of Epidemiological Studies of Cervical Cancer using pooled individual data from 24 studies worldwide, found that current and recent use of combined oral contraceptives, and possibly 5 or more years of progestin-only injectables, was positively associated with cervical cancer. The risk strengthened with duration of use and waned after stopping, reaching that of never users by about 10 years after cessation. Most of the evidence included in the analysis, however, examined cervical cancer risk among the first generation of combined oral contraceptive users exposed to preparations containing a high (50 μg or more) or medium (30-35 μg) dose of oestrogen combined with an older progestin. Furthermore, the duration of use was relatively short. A more recent systematic review and meta-analysis restricted to nine heterogeneous studies did not find an altered cervical cancer risk among ever users of oral contraceptives, odds ratio (OR): 1.21, 95% confidence interval (CI) 0.91-1.61. This meta-analysis, however, did not examine current or recent, or former, use separately. Another limitation was the inclusion of only studies published between 2000 and 2012, in an attempt to assess the effects of oral contraceptives similar to those currently marketed, although several reports were of long-term follow-up of women using older products. Presently, there is very limited direct evidence informing users and their providers about whether contemporary hormonal contraceptives alter cervical cancer risk. We evaluated the risk of cervical cancer among users of hormonal contraception in a large cohort study of virtually all women of reproductive age and living in Denmark; most of whom had not been vaccinated against HPV.

2 | MATERIALS AND METHODS

The previously described Danish Sex Hormone Register Study includes all women aged 15 to 79 years resident in Denmark and aims to investigate hormone use and cancer, cardiovascular and psychiatric diseases. For this analysis, we linked routinely collected data from the National Register of Medicinal Product Statistics (for redeemed prescriptions of all oral and non-oral forms of hormonal contraception since January 1995); Statistics Denmark (for educational attainment); the Danish Cancer Registry (for histologically verified cancers since 1943 and family history of premenopausal breast or ovarian cancer in mothers or sisters); the National Health Register (for hospital discharge diagnoses and surgeries since 1977) and the National Birth Register. Past evidence summarised by the International Collaboration of Epidemiological Studies of Cervical Cancer using pooled individual data from 24 studies worldwide, found that current and recent use of combined oral contraceptives, and possibly 5 or more years of progestin-only injectables, was positively associated with cervical cancer. Little is known about contemporary hormonal contraceptives and cervical cancer risk. In this cohort of mostly unvaccinated women, current or recent use of any hormonal and combined but not progestin-only contraceptives increased cervical cancer risk. The effect strengthened with increasing duration and took longer to decline with prolonged use. The results reinforce the urgency for global interventions to prevent cervical cancer including HPV vaccination programmes, systematic cervical screening and treatment of cervical intraepithelial neoplasia, especially among users of combined contraceptives.

What’s new?

Globally, millions of hormonal contraception users are unvaccinated against human papillomavirus (HPV) infections, which are known to cause cervical cancer. Little is known about contemporary hormonal contraceptives and cervical cancer risk. In this cohort of mostly unvaccinated women, current or recent use of any hormonal and combined but not progestin-only contraceptives increased cervical cancer risk. The effect strengthened with increasing duration and took longer to decline with prolonged use. The results reinforce the urgency for global interventions to prevent cervical cancer including HPV vaccination programmes, systematic cervical screening and treatment of cervical intraepithelial neoplasia, especially among users of combined contraceptives.

2.1 | Statistical analysis

Analyses were conducted using SAS version 9.3 (SAS Institute, Inc, Cary, NC). During the study, women were categorised according to their use of hormonal contraception as current or recent (within 1 year of stopping); former (more than 1 year since stopping) or ever (any hormonal contraceptive use during the study period) users. Never users had no redeemed prescriptions for hormonal contraceptives recorded at study entry or during the study period. If a woman was a never user
on entry to the study and then subsequently redeemed a prescription for a hormonal contraceptive, her contraceptive status changed to current or recent use on the date the prescription was redeemed. Women could switch between current or recent and former user categories depending on prescriptions redeemed. Once a woman became a user of hormonal contraceptives, her contraceptive status could not return to never use. There were fewer periods of observation among never users because many of the women who were never users at study entry subsequently redeemed a prescription for a hormonal contraceptive, at which point their contraceptive status changed.

Age-specific incidence of cervical cancer per 100 000 person-years was calculated for the whole cohort. Using the age distribution of the entire cohort as the standard, age-standardised incidence rates of cervical cancer per 100 000 person-years were calculated for each of the user groups.

Poisson regression was used to calculate the cervical cancer risk among the different user groups, compared to never users. Adjusted rate ratios (hereafter described as relative risk [RR]) with corresponding 95% CIs allowed for time-varying covariates: hormonal contraceptive use, calendar year, age (15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49 years), education (elementary school only, high school only, further education excluding college/university, college/university, university education with research qualifications, unknown), tubal sterilisation (yes/no), endometriosis (yes/no), family history of premenopausal breast or ovarian cancer (yes/no) and parity (nulliparous, 1, 2, 3, 4, >4). Among parous women additional adjustments were made for BMI (<18.5, 18.5-25, >25-30, >30 kg/m²) and smoking status (non-smoker, current, unknown) determined during pregnancy. We could not adjust for any aspects of sexual behaviour (such as age at first intercourse, number of partners or use of barrier contraceptives) since such information is not routinely collected by the national registers used.

Duration (for any hormonal contraception, and users of combined and progestin-only contraceptives separately) and time since last current use were examined, with tests for trend performed by the inclusion of the duration of time since last use variable as an ordinal variable and values set to the median in each category. We examined tumour histology (coded using the International Classification of Diseases for Oncology, 3rd edition, ICD-O-316 all ending with behaviour invasive digit 3) as squamous (M8052, 8070, 8071, 8072, 8076, 8083); adenocarcinoma (M8140, 8144, 8262, 8310, 8380, 8441, 8480, 8490, 9110) and mixed/indeterminate/other (all other morphology codes provided with the C53 cancer registration).

We calculated risk estimates for different products in women followed in the study until their first switch in hormonal contraception, recognising that there might be lingering effects from previous use of hormonal contraceptives. Product-specific risk estimates were also calculated using 30 to 35 μg ethinylestradiol plus levonorgestrel preparations as the reference group. We performed exploratory analyses of risk estimates among the subset of women with complete contraceptive histories that is, those aged 15 on or after 1 January 1995. In this subset, we also examined the number, and effect of, receiving HPV vaccination (since these women were most likely to have been vaccinated).

It is possible that some women begin using, or restart, hormonal contraception because they experience symptoms such as heavy bleeding, which are subsequently attributed to cervical cancer. It is also possible that some women have a cervical smear around the time of beginning or restarting hormonal contraception, providing an opportunity for cervical cancer to be detected. In either situation, a short-term increase in events could be observed among current users of hormonal contraceptives, due to these factors rather than any biological effects of the contraceptives. To investigate whether such protopathic bias might have occurred, we undertook sensitivity analyses in which periods of observation were ignored for 1 year before the date of cervical cancer diagnosis. This resulted in the exclusion of 243 women with less than 1 year of observation before cancer diagnosis.

We did not adjust for multiple comparisons. For the full cohort, we calculated age-standardised absolute risks (incidenceexposed − incidenceunexposed) and the number needed to harm (1/incidenceexposed − incidenceunexposed).

## 3 RESULTS

A total of 2339 incident cervical cancers occurred during 13 235 473 person-years among ever users of hormonal contraceptives and 1304 incident cervical cancers during 7 948 536 person-years among never users. Among ever users of hormonal contraceptives, the median duration of use was 5.02 years (interquartile range 2.03, 8.89 years); the mean duration was 5.87 years (SD = 4.51 years). Combined hormonal contraceptives accounted for 86% of all current or recent hormonal contraceptive use in the study (Table 1). The relatively popular levonorgestrel-releasing intrauterine system (LNG-IUS) and desogestrel-containing progestin-only pills tended to be used by parous rather than nulliparous women, unlike other progestin-only products. Age-specific incidence of cervical cancer increased until age 40, whereupon it fell (Table 1). The age-adjusted incidence of cervical cancer in never users was 14.9 per 100 000 person-years and in ever users of any hormonal contraceptives 17.8 per 100 000 person-years (Table 2). Compared to never users, ever users of any hormonal contraceptives had an increased risk of cervical cancer: RR 1.19 (95% CI 1.10-1.29); driven by an increased risk among current or recent users: RR 1.30 (95% CI 1.20-1.42). Most of the risk associated with hormonal contraception arose from the use of combined contraceptives.

Examined separately, current or recent users of combined contraceptives had an increased risk of cervical cancer: RR 1.40 (95% CI 1.28-1.53), unlike current or recent users of progestin-only contraceptives: RR 0.91 (95% CI 0.78-1.07). Adjustment for BMI and smoking status among parous women did not materially change the risk estimates. For example, an increased cervical cancer risk was found among parous ever users of any hormonal contraceptives: RR 1.10 (95% CI 1.01-1.21) and current or recent users: RR 1.19 (95% CI
1.08-1.31), but not among former users: RR 0.98 (95% CI 0.88-1.09) (data not shown).

In analyses of both any hormonal and combined contraceptives, there was a trend of increasing cervical cancer risk with duration of current use. This relationship was not seen among users of progestin-only products. When the entire dataset was examined, there was no increased risk of cervical cancer among women who were more than 1 year since last current use (Table 2). However, when the data were

| Age group (y) | Cervical cancer (n) | Person-years | Incidence per 100 000 person-years |
|---------------|---------------------|--------------|-----------------------------------|
| 15-19         | <3a                 | 3 155 580    | n/a                               |
| 20-24         | 136                 | 2 878 558    | 4.7                               |
| 25-29         | 455                 | 2 784 600    | 16.3                              |
| 30-34         | 744                 | 2 987 372    | 24.9                              |
| 35-39         | 878                 | 3 213 356    | 27.3                              |
| 40-44         | 825                 | 3 265 173    | 25.3                              |
| 45-50         | 603                 | 2 901 373    | 20.8                              |

aData not available for presentation due to less than three events, incidence estimate therefore not available (n/a) and total person-years rounded to nearest five.

**TABLE 1** Age-specific incidence per 100 000 of cervical cancer during the period 1995 to 2015

**TABLE 2** Relative risk of cervical cancer in users of hormonal contraception (all women)

| Relative Risk | Person-years | Cervical cancer (N) | Age-adjusted incidence/100000 person-years | Adjusted* relative risk (95% confidence interval) | Age-adjusted absolute risk (95% confidence interval)/100 000 |
|---------------|--------------|---------------------|---------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Never use     | 7 948 536    | 1304                | 14.9                                        | 1.00                                             | 1.00                                              |
| Ever use (any hormonal) | 13 235 473 | 2339                | 17.8                                        | 1.19 (1.10-1.29)                                 | 2.9 (1.8 to 4.1)                                  |
| Former use (any hormonal) | 4 412 259 | 872                 | 16.0                                        | 1.02 (0.93-1.13)                                 | 1.1 (0.4 to 2.5)                                  |
| Current or recent use (any hormonal) | 8 823 214 | 1467                | 19.8                                        | 1.30 (1.20-1.42)                                 | 4.9 (3.5 to 6.3)                                  |
| Current or recent use (combined) | 7 745 534 | 1269                | 21.7                                        | 1.40 (1.28-1.53)                                 | 6.8 (5.2 to 8.5)                                  |
| Current or recent use (progestin-only) | 1 077 679 | 198                 | 14.5                                        | 0.91 (0.78-1.07)                                 | –0.4 (–2.7 to 1.9)                                |

**Duration of current use (any hormonal contraception)**

| Relative Risk | Person-years | Cervical cancer (N) | Age-adjusted incidence/100000 person-years | Adjusted* relative risk (95% confidence interval) | Age-adjusted absolute risk (95% confidence interval)/100 000 |
|---------------|--------------|---------------------|---------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| ≤1 y          | 1 262 551    | 173                 | 23.9                                        | 1.37 (1.16-1.61)*                                 | 8.9 (5.1 to 12.8)                                  |
| >1 to ≤5 y    | 4 055 910    | 462                 | 17.2                                        | 1.14 (1.02-1.28)                                 | 2.3 (0.4 to 4.3)                                  |
| >5 to ≤10 y   | 2 576 116    | 527                 | 19.6                                        | 1.40 (1.24-1.57)                                 | 4.7 (2.6 to 6.8)                                  |
| >10 y         | 928 636      | 305                 | 23.0                                        | 1.55 (1.34-1.80)                                 | 8.1 (5.3 to 10.9)                                  |

**Duration of current use (combined)**

| Relative Risk | Person-years | Cervical cancer (N) | Age-adjusted incidence/100000 person-years | Adjusted* relative risk (95% confidence interval) | Age-adjusted absolute risk (95% confidence interval)/100 000 |
|---------------|--------------|---------------------|---------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| ≤1 y          | 1 183 528    | 150                 | 22.8                                        | 1.34 (1.12-1.59)**                                | 7.9 (3.8 to 12.0)                                  |
| >1 to ≤5 y    | 3 641 233    | 410                 | 19.9                                        | 1.25 (1.11-1.41)                                 | 5.0 (2.4 to 7.6)                                  |
| >5 to ≤10 y   | 2 202 125    | 441                 | 20.8                                        | 1.46 (1.28-1.65)                                 | 5.9 (3.3 to 8.5)                                  |
| >10 y         | 718 648      | 268                 | 26.2                                        | 1.76 (1.51-2.05)                                 | 11.3 (8.0 to 14.6)                                 |

**Duration of current use (progestin-only)**

| Relative Risk | Person-years | Cervical cancer (N) | Age-adjusted incidence/100000 person-years | Adjusted* relative risk (95% confidence interval) | Age-adjusted absolute risk (95% confidence interval)/100 000 |
|---------------|--------------|---------------------|---------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| ≤1 y          | 79 023       | 23                  | 27.0                                        | 1.80 (1.19-2.71)**                                | 12.1 (1.0 to 23.2)                                 |
| >1 to ≤5 y    | 414 678      | 52                  | 10.7                                        | 0.71 (0.53-0.94)                                 | –4.2 (–7.4 to –1.0)                                |
| >5 to ≤10 y   | 373 991      | 86                  | 22.0                                        | 1.16 (0.92-1.45)                                 | 7.1 (2.1 to 12.2)                                  |
| >10 y         | 209 988      | 37                  | 10.6                                        | 0.75 (0.54-1.06)                                 | –4.3 (–7.9 to –0.8)                                |

**Time since last current use of any hormonal contraception**

| Relative Risk | Person-years | Cervical cancer (N) | Age-adjusted incidence/100000 person-years | Adjusted* relative risk (95% confidence interval) | Age-adjusted absolute risk (95% confidence interval)/100 000 |
|---------------|--------------|---------------------|---------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| >1 to ≤5 y    | 2 412 582    | 465                 | 16.4                                        | 1.09 (0.97-1.22)†                                  | 1.5 (–0.3 to 3.3)                                  |
| >5 to ≤10 y   | 1 360 077    | 292                 | 16.0                                        | 1.03 (0.90-1.18)                                  | 1.1 (–1.4 to 3.5)                                  |
| >10 y         | 637 600      | 115                 | 11.5                                        | 0.79 (0.65-0.97)                                  | –3.4 (–6.9 to 0.0)                                 |

*p-Trend <.001, **p-Trend <.001, ***p-Trend = .303,
†p-Trend <.001.
*Adjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.
TABLE 3  Relative risk of cervical cancer in hormonal contraceptive users by time since last use and duration of use (all women)

| Duration of use | Time since last current use | Person-years | Events | RR (95% CI)* | Person-years | Events | RR (95% CI)* | Person-years | Events | RR (95% CI)* |
|----------------|----------------------------|--------------|--------|--------------|--------------|--------|--------------|--------------|--------|--------------|
|                | >1 to ≤5 y                 | 659 103      | 104    | 1.07 (0.87-1.31) | 456 734      | 84     | 1.01 (0.81-1.28) | 303 177      | 64     | 1.06 (0.81, 1.40) |
|                | >5 to ≤10 y                | 726 532      | 177    | 1.55 (1.27-1.89) | 282 794      | 67     | 1.37 (1.03-1.83) | 38 225       | 9      | 1.29 (0.65, 2.56) |
|                | >10 y                      | 2 414 582    | 465    |              | 1 360 077    | 292    |              | 637 600      | 115    |

*Adjusted for: calendar year, education, age, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.

stratified by duration of use and time since last use, there was evidence that the risk among women with prolonged use may take longer to disappear (up to 10 years) than the risk among women with shorter-term use (Table 3).

The overall risk estimates in the subset of women followed until their first switch in hormonal contraceptive were of similar magnitude to those seen in the full cohort (Table 4). We had insufficient data to calculate risk estimates for some of the products used including vaginal rings and contraceptive patches. Overall, there was little evidence of major differences in risk between combined products containing different progestins. Analyses where 30 to 35 μg ethinylestradiol plus levonorgestrel products formed the referent group (Table 2S), and when product-specific estimates were calculated among the full cohort (Table 3S), also found few differences between products. In both analyses, current or recent users of the LNG-IUS had a reduced risk of cervical cancer when compared to current or recent users of 30 to 35 μg ethinylestradiol plus levonorgestrel products.

Larger, but very imprecise, point estimates were observed in the exploratory analysis among women with full contraceptive history (<14 706 women using combined contraceptives for 1 year). Former users of any hormonal contraception had an increased risk of cervical cancer in this subset analysis: RR 4.35 (95% CI 1.57-12.00). More than three-quarters of former users had stopped within the previous 5 years (data not shown). In this subset, current or recent use of progestin-only products was associated with increased cervical cancer risk: RR 3.38 (95% CI 1.13-10.10). There was little evidence of differences in risk estimates of combined products containing different progestins (Table 4S). Former users of any hormonal contraception and combined contraceptives did not increase the risk of cervical cancer (Table 7S).

Age-adjusted absolute risks were calculated for the main patterns of contraceptive use in the entire cohort (Table 2). The age-adjusted absolute risk of cervical cancer among current or recent use of combined contraceptives was 6.8 per 100 000 (95% CI 5.2-8.5) person-years; approximately one extra case of cervical cancer for every 14 706 women using combined contraceptives for 1 year.

4  | DISCUSSION

In this cohort study of mostly women unvaccinated for HPV, current or recent use of any hormonal contraception and combined contraception, but not progestin-only contraception, was associated with an increased risk of cervical cancer; an effect which strengthened with increasing duration of use. The increased risk of cervical cancer among women with prolonged use appeared to take up to 10 years to disappear after stopping. Where there was sufficient use of products to permit analysis, there was little evidence of material differences in risk between different combined preparations. Current or recent use of any hormonal contraception was positively associated with both squamous and adenocarcinoma types of cervical cancer.

Our results indicate that currently used combined oral contraceptives are associated with a similar pattern of cervical cancer risk as that of older preparations, at least among women not vaccinated against HPV. We had insufficient data to assess robustly the risk associated with combined contraceptive patches or vaginal rings. Most studies published since the International Collaboration’s publication have investigated ever use of combined oral contraception. Several reported an increased risk of cervical cancer with prolonged use, and a waning risk with increasing time since last use. None of the other studies provided product-specific estimates. We found little evidence of major differences in risk between combined products containing different progestins.

Based on 10 studies (out of 24 overall), the International Collaboration found an increased risk of cervical cancer in women with 5 or
| Relative risk of cervical cancer among users of different hormonal contraceptives in women followed up until first switch in hormonal contraceptive |
|-------------------------------------------------|-----------------|---------------------------------|
| **Person-years** | **Cervical cancer (N)** | **Adjusted relative risk (95% confidence interval)** |
| **Never use** | 7 948 536 | 1304 | 1.00 |
| **Ever use (any hormonal)** | 7 127 336 | 1135 | 1.18 (1.08-1.28) |
| **Former use (any hormonal)** | 2 540 968 | 491 | 1.04 (0.93-1.17) |
| **Current or recent use (any hormonal)** | 4 586 368 | 644 | 1.29 (1.16-1.42) |
| **Current or recent use (combined)** | 4 313 847 | 603 | 1.36 (1.22-1.51) |
| **Current or recent use (progestin-only)** | 272 521 | 41 | 0.77 (0.57-1.06) |

**Current or recent use of combined hormonal contraception**

| **Oral** |
|-------------------------------------------------|--------------|
| Norethisterone 50 μg EE | 36 407 | 18 | 2.69 (1.68-4.28) |
| Levonorgestrel 50 μg EE | 47 171 | 15 | 1.59 (0.95-2.64) |
| Norethisterone 30-35 μg EE | 115 988 | 23 | 1.73 (1.14-2.63) |
| Levonorgestrel 30-35 μg EE | 518 647 | 123 | 1.48 (1.23-1.79) |
| Desogestrel 20-30 μg EE | 988 333 | 112 | 1.21 (0.99-1.48) |
| Gestodene 20-35 μg EE | 1 885 998 | 240 | 1.31 (1.13-1.52) |
| Drospirenone 20-35 μg EE | 188 850 | 9 | 1.13 (0.58-2.19) |
| Norgestimate 35 μg EE | 375 464 | 48 | 1.35 (1.01-1.80) |
| Cyproterone 30 μg EE | 142 001 | 14 | 1.01 (0.59-1.71) |
| Estradiol valerate, dienogest | 1010 | <3 | n/a |

| **Non-oral** |
|-------------------------------------------------|--------------|
| Patch | 2250 | <3 | n/a |
| Vaginal ring | 11 730 | <3 | n/a |

**Current or recent use of progestin-only contraception**

| **Oral** |
|-------------------------------------------------|--------------|
| Norethisterone | 66 790 | 10 | 0.75 (0.40-1.40) |
| Levonorgestrel | 6955 | <3 | n/a |
| Desogestrel | 12 110 | <3 | n/a |

| **Non-oral** |
|-------------------------------------------------|--------------|
| MPA depot | 7315 | <3 | n/a |
| Implant | 10 555 | <3 | n/a |
| LNG-IUS | 168 801 | 27 | 0.76 (0.52-1.11) |

**Duration of current use (any hormonal contraception)**

| **≤ 1 y** | 1 059 532 | 135 | 1.30 (1.08-1.56) |
| **>1 to ≤ 5 y** | 2 309 695 | 241 | 1.12 (0.97-1.29) |
| **>5 to ≤ 10 y** | 960 337 | 185 | 1.43 (1.21-1.70) |
| **>10 y** | 256 804 | 83 | 1.66 (1.31-2.11) |

**Duration of current use (combined)**

| **≤ 1 y** | 1 000 606 | 120 | 1.29 (1.07-1.57) |
| **>1 to ≤ 5 y** | 2 144 034 | 223 | 1.24 (1.06-1.44) |
| **>5 to ≤ 10 y** | 919 330 | 177 | 1.48 (1.24-1.75) |
| **>10 y** | 249 877 | 83 | 1.69 (1.33-2.15) |

**Duration of current use (progestin-only)**

| **≤ 1 y** | 58 926 | 15 | 1.46 (0.87, 2.42) |
| **>1 to ≤ 5 y** | 165 660 | 18 | 0.56 (0.35, 0.89) |
| **>5 to ≤ 10 y** | 41 007 | 8 | 0.96 (0.48, 1.93) |
| **>10 y** | 6930 | <3 | n/a |
more years of progestin-only injectable contraceptive use: RR 1.22 (95% CI 1.01-1.46). Risk estimates for progestin-only oral contraceptives could not be calculated. The Johannesburg Cancer Case Control Study examined progestin-only injectable use and cervical cancer and found that exclusive users of progestin-only injectables less than 10 years previously were more likely to be diagnosed with cervical cancer than never users of hormonal contraceptives: OR 1.58 (95% CI 1.16-2.15). When time since last use and duration of use were examined simultaneously, cervical cancer risk diminished with increasing time since last use, without a relationship to duration of use. The results from both of these studies suggest an increased risk of cervical cancer among progestin-only injectable users. The use of MPA depot was rare in our cohort. Our main analyses did not reveal an increased risk with current or recent use of any progestin-only contraceptives regardless of route of administration. The use of LNG-IUS was rare in our cohort. Our main analyses did not reveal an increased risk with current or recent use of any progestin-only contraceptives regardless of route of administration. The absence of cervical cancer risk among LNG-IUS users supports findings from a nationwide cohort study of Finnish women aged 30-49 years using the LNG-IUS for menorrhagia, which found a standardised incidence ratio (SIR) of 0.90 (95% CI 0.69-1.15) for all cervical cancer and SIR 1.18 (95% CI 0.74-1.79) for cervical adenocarcinoma.

Strengths of our study include the ability to examine all types of hormonal contraceptives used between 1995 and 2014 among a nearly whole nation cohort of more than 1.8 million women of reproductive age, observed for over 21 million person-years. Information about both redeemed prescriptions for hormonal contraceptives and incident cervical cancers are routinely collected prospectively by the National Registers, thus avoiding information bias. When considering specific products, our main risk estimates were calculated among women followed until their first switch in hormonal contraceptive in the study, to reduce the possibility that a risk estimate for a particular product might reflect lingering effects from another previously used hormonal contraceptive(s). There was little evidence of important differences in risk estimates for combined contraceptives containing different progestins. Compatible results were found in the exploratory analyses of women with a full contraceptive history, although the risk estimates were much less precise because they were based on fewer cervical cancers (n = 285) and less periods of observation (25%) than

### Table 4

| Time since last current use of any hormonal contraception | Person-years | Cervical cancer (N) | Adjusted* relative risk (95% confidence interval) |
|----------------------------------------------------------|--------------|---------------------|-------------------------------------------------|
| >1 to ≤5 y                                               | 1 267 925    | 225                 | 1.08 (0.93-1.25)                                |
| >5 to ≤10 y                                              | 808 397      | 180                 | 1.10 (0.93-1.30)                                |
| >10 y                                                    | 464 646      | 86                  | 0.85 (0.67-1.08)                                |

Note: <3: data not available for presentation due to less than three events, estimate therefore not available (n/a) and total person-years rounded to nearest five.

Abbreviations: EE, ethinylestradiol; LNG-IUS, levonorgestrel-releasing intrauterine system.

*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.

### Table 5

| Histology                  | Person-years | Cervical cancer (N) | Adjusted* relative risk (95% confidence interval) |
|----------------------------|--------------|---------------------|-------------------------------------------------|
| Squamous                   |              |                     |                                                 |
| Never use                  | 7 948 536    | 991                 | 1.00                                            |
| Current or recent use       | 8 823 214    | 1090                | 1.31 (1.19-1.44)                                |
| Former use                 | 4 412 259    | 639                 | 1.03 (0.92-1.15)                                |
| Adenocarcinoma             |              |                     |                                                 |
| Never use                  | 7 948 536    | 209                 | 1.00                                            |
| Current or recent use       | 8 823 214    | 257                 | 1.29 (1.05-1.60)                                |
| Former use                 | 4 412 259    | 160                 | 0.98 (0.77-1.24)                                |
| Mixed/indeterminate/other  |              | 297                 |                                                 |
| Never use                  | 7 948 536    | 104                 | 1.00                                            |
| Current or recent use       | 8 823 214    | 120                 | 1.29 (0.95-1.74)                                |
| Former use                 | 4 412 259    | 73                  | 1.08 (0.76-1.52)                                |

*Adjusted for: calendar year, age, education, parity, family history of breast or ovarian cancer, tubal sterilisation and endometriosis.
in the main analysis. Although we could adjust for several possible confounders, we lacked information about cervical screening, age at first intercourse or number of sexual partners so residual confounding could have occurred. That said, the International Collaboration found similar patterns of risk among women likely to have been screened as among those not screened, and in the subgroup of women who tested positive for high-risk HPV compared to all women studied. Information about lifetime number of sexual partners was available in all of the case-control but none of the cohort studies included in the pooled analysis. However, there was little difference in results using all studies, compared to the findings of only case-control studies that is, the patterns of increased cervical cancer risk associated with oral contraceptive use persisted after adjustment for sexual behaviour. Adjustment for HPV serology did not materially change the cervical cancer and oral contraceptive use findings from the European Prospective Investigation into Cancer and Nutrition.23 We could adjust for BMI and smoking status only among parous women, and then for only part of the follow-up period. Although these adjustments did not substantially alter the risks estimates, again it is possible that our results are subject to residual confounding. Previous studies have suggested that users of combined oral contraceptives are more likely to smoke than non-users of these contraceptives.10,24 If this remains the case, incomplete adjustment for smoking may have overestimated the risk of cervical cancer among combined contraceptive users.

Hormonal contraceptives may exert molecular effects through which persistent HPV infection leads to cervical cancer. For example, oestrogen and progestin might promote HPV 16 E6 and E7 oncogene expression, stimulating p53 tumour suppressor gene degradation and viral DNA integration and transformation of cells to induce cancer development.8,23,27 Other postulated mechanisms include, changed cervical susceptibility to HPV infection, or altered HPV infection natural history leading to reduced clearance.8,23,27 It is not clear whether and how these mechanisms might be different for progestin-only contraceptives.

The Danish childhood immunisation programme for 12-year-old girls has included HPV vaccination since 2009.28 Thus, our findings reflect the risks associated with hormonal contraception in a predominantly unvaccinated cohort. The absence of material change after adjusting for HPV vaccination in the full contraceptive subset was likely due to the small proportion of person-time attributable to HPV vaccinated women. Given recent evidence from Sweden that girls and women aged 10 to 30 who received the quadrivalent HPV vaccination had a substantially reduced risk of invasive cervical cancer,29 we await the opportunity to determine whether HPV vaccination within our cohort reduces cervical cancer incidence. Such an effect would increase the number needed to harm from combined oral contraceptive use.

In our cohort of women mostly unvaccinated for HPV, we estimate that one extra case of cervical cancer occurred in our cohort for every 14 706 women who used contemporary combined contraception for 1 year. The absolute risk will be higher in countries where cervical cancer is more common than in Denmark; countries where comprehensive screening and HPV vaccination programmes are often absent and where perhaps two-thirds of all hormonal contraceptive users live. Women should be informed of the association between contemporary combined contraception and cervical cancer, an effect which is enhanced by prolonged use but which disappears some years after stopping. Such information should be balanced against high levels of protection against pregnancy and its associated mortality and morbidity, and other important non-contraceptive benefits including large sustained protection against ovarian30 and endometrial21 cancer.

Our results indicate that currently available combined contraceptives continue to be positively associated with the risk of cervical cancer, at least among women not vaccinated against HPV. Women wishing to use this method of contraception need to be informed of this risk and encouraged to participate in a cervical screening programme, if available. They should also be alert to any symptoms indicative of cervical cancer, and report these promptly to their health care provider. Our findings also reinforce the urgent public health need for global interventions to prevent cervical cancer.

**CONFLICT OF INTEREST**
The authors declare no conflict of interest.

**DATA AVAILABILITY STATEMENT**
The study data are held with the secure data depository at Statistics Denmark, permissions to access can only be granted by Statistics Denmark (https://www.dst.dk/en/TilSalg/Forskningsservice). Further details that support the findings of this study are available from the corresponding author upon request.

**ETHICS STATEMENT**
Ethical approval is not required for register-based studies in Denmark. Approval was obtained from the Health Data Board and Danish Data Protection Agency. The data were analysed (by SF) and held within the secure data repository at Statistics Denmark, with personal identification numbers encrypted.

**ORCID**
Lisa Iversen https://orcid.org/0000-0002-2524-5229

**REFERENCES**
1. GLOBOCAN 2018: Cervix uteri. Cancer incidence and mortality statistics worldwide and by region. http://gco.iarc.fr/today/data/factsheets/cancers/23-cervix-uteri-fact-sheet.pdf. Accessed 19 June 2019.
2. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
3. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4:e453-e463.
4. WHO estimates of human papillomavirus immunization coverage, 2019 update. https://www.who.int/immunization/monitoring_surveillance/data/HPV_estimates.xls?ua=1. Accessed 30 September 2020.
5. Garland SM, Stanley MA, Giuliano AR, et al. IPVS statement on “Temporary HPV vaccine shortage: implications globally to achieve equity”. Papillomavirus Res. 2020;9:100195.
6. Gadducci A, Barsotti C, Cosio S, Domenici L, Genazzani AR. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011;27:597-604.

7. United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435); 2019.

8. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609-1621.

9. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22:1931-1943.

10. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study. BMJ. 2007;335:651.

11. Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013;88:678-683.

12. March LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø. Hormone therapy and ovarian cancer. JAMA. 2009;302:298-305.

13. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257-2266.

14. World Health Organization. International Statistical Classification of Diseases and Health Related Problems, 10th Revision. Geneva: World Health Organization; 1992.

15. Shafirir AL, Schock H, Poole EM, et al. A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964. Cancer Causes Control. 2017;28:371-383.

16. Fritz A, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.

17. Nojomi M, Modaresgilani M, Mozafari N, Erfany A. Cervical cancer and duration of using hormonal contraceptives. Asia Pac J Clin Oncol. 2008;4:107-112.

18. Vanakankovit N, Taneepanichskul S. Effect of oral contraceptives on risk of cervical cancer. J Med Assoc Thai. 2008;91:7-12.

19. Rosenblatt KA, Gao DL, Ray RM, et al. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control. 2009;20:27-34.

20. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010;340:c927.

21. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med. 2012;9:e1001182.

22. Charlton BM, Rich-Edwards JW, Colditz GA, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. BMJ. 2014;349:g6356.

23. Roura E, Travier N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC Cohort. PLoS One. 2016;11:e0147029.

24. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet. 2003;362:185-191.

25. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifet ime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1-580.e9.

26. Soini T, Hurskainen R, Grönnmän S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124:292-299.

27. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.

28. Thamsborg LH, Andersen B, Larsen LG, et al. Danish method study on cervical screening in women offered HPV vaccination as girls (Trial23): a study protocol. BMJ Open. 2018;8:e020294.

29. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340-1348.

30. Iversen L, Fielding S, Lidegaard Ø, March LS, Skovlund CW, Hannaford PC. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ. 2018;362:k3609.

31. Iversen L, Fielding S, Lidegaard Ø, Hannaford PC. Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women. Contraception. 2020;102:152-158.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Iversen L, Fielding S, Lidegaard Ø, Hannaford PC. Contemporary hormonal contraception and cervical cancer in women of reproductive age. Int. J. Cancer. 2021;149:769–777. https://doi.org/10.1002/ijc.33585